NP Consortium

Longitudinal study of early markers of Alzheimer’s disease in adults who have Trisomy 21 (Horizon 21 cohort)

Progress of the project

Patient monitoring

In collaboration with:

Consortium Horizon 21

Number of patients 19/20

Duration 4 years

Purpose of the study

The purpose of this study is to identify suitable diagnostic tools, and especially a new version of a neuropsychological test (CAMCOG-DS), that will allow for a better, earlier diagnosis of Alzheimer’s disease in patients with Trisomy 21.

The CAMCOG-DS neuropsychological test is used to assess various areas of cognitive function, such as orientation, language, memory, praxis, perception and executive functions.

A multicenter study

This research project is coordinated at European level by the University of Cambridge (UK). The countries that are members of the Horizon 21 Consortium are contributing.

In total, 180 people with Trisomy 21, aged 25 or older, should be enrolled in the project, which amount to 20 patients per investigation center.

How is the study conducted?

The study includes several visits at the Institute, including a medical check-up, neuropsychological tests as well as blood sampling.

During the course of the study, the patient should have a total of 5 visit: 1 baseline visit and 1 monitoring visit per year for 4 years.